In this study, we developed AAV8-RedO-CD47, a gene therapy vector that protected cones and vision in multiple models of RP (Supplemental Table 1), suggesting it as a potential generic treatment for patients with different mutations. Here, CD47 is linked to retinitis pigmentosa 1.